Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of axalimogene filolisbac (ADXS-HPV) in combination with epacadostat (INCB-24360) in patients with HPV-associated cervical cancer

Trial Profile

Phase II trial of axalimogene filolisbac (ADXS-HPV) in combination with epacadostat (INCB-24360) in patients with HPV-associated cervical cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axalimogene filolisbac (Primary) ; Epacadostat (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Sponsors Advaxis; Ayala Pharmaceuticals; Incyte Corporation
  • Most Recent Events

    • 19 Jan 2023 According to an Ayala Pharmaceuticals media release, Advaxis merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals.
    • 08 Jan 2016 According to an Advaxis Immunotherapies media release, this trial is expected to commence in the first half of 2016.
    • 01 Dec 2015 According to the Advaxis Inc. media release, the US FDA has granted orphan drug designation for axalimogene filolisbac in the treatment of cervical cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top